# Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

> **NCT03150706** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03150706
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-22
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150706, "Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03150706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*